HOME >> MEDICINE >> NEWS
Investigational drug may protect cancer and AIDS patients from side effects of pain relief therapy

A drug developed to relieve one of the major side effects of pain therapy for cancer patients may offer an added benefit for AIDS patients, researchers from the University of Chicago and the Children's Hospital of Philadelphia reported Saturday, October 11, at the 2003 Annual Meeting of the American Society of Anesthesiologists in San Francisco.

Methylnaltrexone (MNTX) was invented to reverse the constipation caused by powerful opioid-based pain relievers such as morphine, OxyContin or Percocet taken by patients with cancer or AIDS. Opiates also appear to increase the ability of HIV to infect certain immune system cells.

This laboratory study found that MNTX blocked increases in HIV entry and replication that occur when immune cells are exposed to therapeutic doses of morphine. In this in-vitro study, very small amounts of methylnaltrexone blocked this process.

"If our studies are borne out in future clinical trials, methylnaltrexone may improve the care of patients who take opioids for pain caused by AIDS," said Jonathan Moss, M.D., Ph.D., professor of anesthesia and critical care at the University of Chicago and director of the study.

Many AIDS patients and more than 500,000 patients with advanced cancer depend on drugs like morphine for pain relief. One side effect of these pain relievers is severe constipation, which can be so distressing that many patients discontinue their pain medication.

Methylnaltrexone was invented to solve this problem by the late Leon Goldberg, a University of Chicago pharmacologist. To help a dying friend with morphine-induced constipation, Goldberg took naltrexone, an established drug that blocks the effects of morphine, and altered it slightly so that it could no longer cross the protective barrier that surrounds the brain.

Consequently, it did not interfere with morphine's effect on pain, which is centered in the brain, but it did block morphine's effects on gut motility, which a
'"/>

Contact: John Easton
jeaston@uchospitals.edu
773-702-6241
University of Chicago Medical Center
14-Oct-2003


Page: 1 2

Related medicine news :

1. Investigational transplant drug effectively preserves kidneys while avoiding toxic side effects
2. Investigational drug may provide new option for preventing transplant organ rejection
3. Investigational drug brings new hope to kidney cancer patients
4. Investigational mesh jackets studied as an experimental therapy for heart failure
5. Investigational oral contraceptive reduces premenstrual and menstrual symptoms
6. Investigational drug study may determine if lung cancer is preventable in cigarette smokers
7. New study in Nature demonstrates protection against cell death during heart attack
8. Simple intervention encourages sun protection behaviors
9. Red wine protects the heart
10. Sunflower seed oil can protect low birth weight babies from infection
11. Physical activity linked to protection from Parkinsons disease

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/21/2017)... ... January 21, 2017 , ... Pacifica Graduate Institute’s Alumni ... line-up of events for its annual meeting “Coming Home 2017,” an activity-packed weekend ... Home 2017” will be held on Friday January 27 through Sunday, January 29, ...
(Date:1/21/2017)... ... 2017 , ... The Nobel Biocare™ dental implant company is ... its creos™ line of bone regenerative products. Specifically, the Nobel Biocare™ ... creos™ allo.gain™ bone graft for a variety of bone reconstruction procedures. In addition ...
(Date:1/20/2017)... ... January 20, 2017 , ... Source Vitál Apothecary, a skin ... pure essential oils, announced the company had a successful visit to the 2017 ECRM ... event gives companies that work in the nutritional, sports and health industries a chance ...
(Date:1/20/2017)... ... January 20, 2017 , ... ATP Science, an Australian-based company ... attended the January ECRM Trade Show in Hilton Head, SC, benefiting from outstanding ... range of supplements that keep the body functioning at its peak performance by ...
(Date:1/20/2017)... ... January 20, 2017 , ... Vitamin Well has launched two ... drinks have been produced in collaboration with Zlatan Ibrahimovic and have been developed ... After a successful launch in Sweden last year, the next generation sports drinks ...
Breaking Medicine News(10 mins):
(Date:1/20/2017)... 2017  Palladian Health, a leading provider of ... of an opioid management program which assists physicians ... helps stem the growing tide of dependence on ... chronic non-cancer pain (back pain, neck pain, and ... of evidence regarding long-term effectiveness. The ...
(Date:1/20/2017)... January 20, 2017 Avillion LLP, a co-developer ... Mark Weinberg , MD MBA as Chief Medical Officer. Dr ... USA . ... Dr Weinberg has spent more than 17 years as a ... companies to micro-cap biotech. Over the course of his career, he ...
(Date:1/19/2017)... -- Report Details What can be expected ... to grow at the fastest rates? This visiongain report ... opportunities and prospects. Our 190-page report provides 124 ... in the industry and the future market prospects. Our ... all the major categories of the ophthalmic devices market. ...
Breaking Medicine Technology:
Cached News: